title: Carcinoma of the uterine cervix: review of experience at University of Kansas Medical Center.
abstract: A total of 211 patients with a diagnosis of carcinoma of uterine cervix, managed by radiotherapy at the University of Kansas Medical Center between 1969-1975 was reviewed. There were 90 patients in Stage I, 65 in Stage II, 43 in Stage III, and 13 with Stage IV disease. Squamous cell carcinoma was found to be the most common histologic type. Twenty-three patients had shown uterine extension of the disease; of these, eight had adenocarcinoma. The majority of the patients received external whole-pelvic telecobalt therapy followed by a variety of intracavitary radium applications. The combined dose to point A ranged from 5000-13,000 rad. There were 166 patients followed for five or more years. Overall five-year survival was 74% (124/166). Survival by stage: IA--92% (12/13); IB--88% (55/62); IIA2--74% (23/31); IIB--58% (14/24); IIIA&B--64% (18/28); and IV--25% (2/8). The overall three-year survival was 73% (155/211). Thirty-three patients (33/211 = 16%) developed local recurrence, and five of these patients were salvaged by surgery. Surgery for complications was required in nine patients. Rectovaginal and vesicovaginal fistulae occurred in three patients (1.5%). Local recurrence and complications vs. dose and system used were analyzed.
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*